About Immunologik

The ImmunoLogik GmbH develops a novel class of substances for the fight against viral infections

IML-206 against SARS-CoV-2 and other coronaviruses

THE CHALLENGE

Since the outbreak of SARS-CoV-2 several million people got infected with this virus and several hundred thousand people already died due to the consequences of COVID-19. Coronaviruses are a recurring and ongoing pandemic of the 21st century. In the last two decades three coronaviruses emerged, SARS, MERS and SARS-CoV-2, and caused life-threatening diseases. So far, no vaccine or specific antiviral therapy for SARS-CoV-2 exist. Current repurposed drugs in clinical development either have many side effects or have a high risk for the development of drug resistances, because they target components of the genetically variable viruses. Therefore, an urgent medical need for a reliable and tolerable broad-spectrum antiviral drug without the risk of resistant virus variations exists.

OUR SOLUTION APPROACH

IML-206 as a broad-spectrum antiviral drug for the treatment of patients infected with SARS-CoV-2 or other (future) coronaviruses. Unlike many other developments, the innovative substance IML-206 blocks specific cellular structures in humans, which are very likely indispensable for the replication of a broad range of coronavirus variants.

IML-106 against HIV

THE CHALLENGE

Worldwide more than 36 million people live with an HIV infection and thus with the expectation to develop AIDS sooner or later. Despite the available combined antiretroviral therapy, AIDS is far from being defeated. With an array of drugs, the therapy targets viral components and suppresses the replication of the virus and therewith in most cases the outbreak of the fatal AIDS disease. Due to the high mutation rate of the virus, new variations increasingly resistant against the existing drugs arise constantly. Additionally, many drugs cause severe side effects and cannot be permanently taken by a large number of patients. Therefore, despite the modern combined antiretroviral therapy annually around 22 000 HIV-infected alone in Western and Central Europe as well as USA die from the consequences of AIDS.

OUR SOLUTION APPROACH

IML-106 for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS. The lead candidate targets directly the components of the host cell, which are essential for the replication of HIV. The goal is to significantly reduce the risk of resistant virus variations.

Our Team

The highly qualified ImmunoLogik team

Dr. Christian Setz

Dr. Christian Setz

Scientific Managing Director

  • Co-inventor of ImmunoLogik’s lead candidates IML-106 and IML-206
  • PhD thesis in molecular virology at the Friedrich-Alexander-University Erlangen-Nuremberg
  • More than 15 years’ experience in virology
  • Former project leader of an independent HIV-1 research group at the Institute for Clinical and Molecular Virology in Erlangen
  • Extensive research contributions in the development of novel antiretroviral strategies by deciphering molecular mechanisms, which regulate the functions of viral proteins and their cellular counterparts
  • Scientific publications in leading international science journals
  • Numerous active participations in renowned national and international virology congresses

Prof. Dr. Ulrich Schubert

Prof. Dr. Ulrich Schubert

Scientific adviser

  • Co-founder of ImmunoLogik GmbH
  • Doctoral thesis in biochemistry at the University of Leipzig
  • Former group leader and staff scientist at the Department of Medical Immunology of the Medical Faculty of the Charité, Humboldt University Berlin
  • Habilitation in “Experimental Virology” at the University of Hamburg
  • 10 years at the National Institute of Allergy and Infectious Diseases in Bethesda, USA
  • Since 2003 professor for virology at the Institute for Clinical and Molecular Virology in Erlangen
  • 88 publications in renowned international science journals and more than 45 patent applications
  • Substantially involved in the development of the blockbuster drug VELCADE® (bortezomib) by Millennium Pharmaceuticals Inc.

Günter Frankenne

Günter Frankenne

Strategic advisor

  • More than 30 years of experience as:
  • CEO Sandoz AG, managing director Novartis GmbH and Wander Pharma GmbH
  • Committee member and chairman of the Federal Association of the Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie)
  • Vice chairman of the Association of Research-based Pharmaceutical Companies (Verband Forschender Arzneimittelhersteller)
  • 10 years board member of Forum MedTech Pharma

Lars Siegert

Lars Siegert

Commercial Managing Director

  • Studies of Business Law LL.B. at University of Applied Sciences Osnabruck, Business Management with Law at Napier University Edinburgh B.A. with Honours and Business Developments M.A. at Leuphana University Luneburg
  • Business Development Manager at Athenion Group since 2016
  • Since then involved in the business development of the ImmunoLogik
  • Previously worked in the Business Development of different organizations in various industries
  • Several years' of experience as Management Consultant for DAX- and other global blue chip corporations
  • Work experience in UK, USA and Indonesia

Ekkehard Brysch

Ekkehard Brysch

Board member of Athenion AG and advisor

  • Studies of business administration and law at University of Göttingen
  • 25 years’ experience in international management consulting
  • Certified Management Consultant (CMC) and member of Association of German Management Consultants (Bundesverband Deutscher Unternehmensberater)
  • Certified Management Consultant (CMC) and member of Association of German Management Consultants (Bundesverband Deutscher Unternehmensberater)
  • 18 years’ experience in pharmaceutical development and investment business
  • Vice-president of the Board of Directors of Athenion AG & MetrioPharm AG
  • Represents Athenion AG as anchor investor

ATHENION-GROUP

ATHENION-GROUP

  • Successful in the development of pharmaceutical projects for more than 18 years
  • Enables ImmunoLogik to gain access to interdisciplinary expert teams from drug development, project and quality management, specialists in business development and patent law
  • Preserves necessary corporate infrastructure for the ImmunoLogik for a reasonable price

"Despite the modern combined antiretroviral therapy, annually 22 000 HIV-infected alone in Western and Central Europe as well as USA die from the consequences of AIDS. We founded the ImmunoLogik with the goal to give hope to the patients who have exploited the means of the standard therapy, and cannot be helped by it anymore."

Prof. Dr. Ulrich Schubert

"ImmunoLogik is working on a novel and holistic approach for the treatment of HIV-infected patients, where the standard therapy proves to be largely ineffective. The for the development success important combination of scientific expert knowledge, industry expertise and patent protection is ensured by the close cooperation of science and industry experts. The interdisciplinary team work is an essential basis for the further successful drug development for the benefit of the affected patients."

Günter Frankenne

News

The ImmunoLogik wishes a merry Christmas and a happy New Year 2021

December 21, 2020

The ImmunoLogik wishes all people involved in the project, partners and supporters a merry Christmas and a happy New Year 2021.

Withou a doubt 2020 was a special year for everyone and in particular for ImmunoLogik, which is engaged in the fight against virusinfections. We are grateful for the support received and various engagement from countless companions in 2020. This gives us confidence to continue resolutely and with full vigor on the chosen path in future.

Read More

Contact

How to contact us: